BenzingaAugust 11, 2026 at 12:55 PM NY24 days ago

Aardvark Therapeutics Q2 EPS $(0.66) Beats $(0.91) Estimate

Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.91) by 27.47 percent. This is unchanged from the same period last year.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Read at Source

Companies in This Story

AARDAardvark Therapeutics Inc5.38− 6.11%

Companies in This Story

Related Stories